Efficacy and safety of long term high-dose atorvastatin in elderly patients with hypertension complicated with coronary heart disease
-
摘要: 目的 比较评价40 mg/d与20 mg/d的阿托伐他汀连续使用24个月对老年高血压合并冠心病的有效性及安全性,为临床上老年高血压合并冠心病的合理用药提供新的参考依据。 方法 将温州市中西医结合医院2016年1月-2018年6月收治的150例 ≥ 60岁高血压合并冠心病患者随机分配到高剂量组和常规剂量组,每组各75例,高剂量组给予阿托伐他汀40 mg/d,常规剂量组给予阿托伐他汀20 mg/d,治疗前、治疗后第12个月和24个月分别测定2组的血压、血脂、颈动脉内-中膜厚度(IMT)及斑块面积,记录可能的药物不良反应,数据采用SPSS 21.0统计软件进行分析。 结果 高剂量组和常规剂量组治疗前、治疗后第12和24个月3个时间点的血压、血脂、IMT和斑块面积差异均有统计学意义(均P<0.05),治疗后第12和24个月时,高剂量组的收缩压、血脂、IMT和斑块面积分别与同期常规剂量组的同一指标比较,差异均有统计学意义(均P<0.05),但舒张压的差异无统计学意义(P>0.05),2组不良反应率差异无统计学意义(P>0.05)。 结论 40 mg/d和20 mg/d阿托伐他汀均能改善高血压合并冠心病患者的血压、血脂、IMT及斑块面积,高剂量组改善效果优于常规剂量组,没有证据提示长达24个月大剂量服用阿托伐他汀会增加不良反应的发生几率,相关结果有待高质量的多中心随机对照试验进一步验证。Abstract: Objective To evaluate the efficacy and safety of 40 mg/d and 20 mg/d's atorvastatin lasted 24 months for elderly hypertension combined with coronary heart disease, and to provide a new reference for rational use of drug. Methods From January, 2016 to June, 2018, 150 patients with hypertension and coronary heart disease above 60 years old were randomly assigned to a high dose group and a conventional dose group, with 75 cases in each group. The high dose group was given 40 mg/d of atorvastatin, and the routine dose group was given 20 mg/d of atorvastatin, and two groups were measured before, twelfth months and twenty-fourth months after treatment. Blood pressure, blood lipids, carotid in-middle membrane thickness (IMT) and plaque area were recorded, and possible adverse drug reactions were analyzed by SPSS 21.0. Results There were significant differences in blood pressure, blood lipid, carotid artery and middle membrane thickness (IMT) and plaque area at the three time points before treatment, 12 and 24 months after treatment about the high dose group and the routine dose group (P<0.05). Compared with systolic pressure, blood lipid, IMT and plaque area, there were significant differences between the high dose group and the routine dose group at 12 and 24 months after treatment(P<0.05),but the diastolic pressure difference was not statistically significant (P>0.05), and there was no significant difference in adverse reaction rate between the two groups (P>0.05). Conclusion Forty mg/d and 20 mg/d atorvastatin can effectively remedy blood pressure, blood lipid, IMT and plaque area in patients with hypertension and coronary heart disease, and the effect of high dose improvement is better than that of the conventional dose group. There is no evidence that 24 months large dose of atorvastatin can increase the incidence of adverse reactions, and the results need further validation by high-quality multicenter randomized controlled trials.
-
Key words:
- Atorvastatin /
- Hypertension combined with coronary heart disease /
- Safety
点击查看大图
计量
- 文章访问数: 213
- HTML全文浏览量: 31
- PDF下载量: 1
- 被引次数: 0